SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert Mayo who wrote (266)10/23/1998 5:11:00 PM
From: John Patterson  Read Replies (3) of 712
 
All IMHO but I think the move by CORR is due to anticipation that Integrillin in cutting into the sales of ReoPro. I know at our center the majority of the cardiologists are switching to Integrillin due to the 1. cost (about 1/3 of ReoPro, also favored by the Pharmacy)and 2. quick reversibility. I am a clinical perfusionist in cardiac surgery and when we receive an emergency patient from the cath lab that has had ReoPro there is a high probability that we will end up having to transfuse that patient with Platlets in order to control bleeding postoperatively. That is not the case with Integrillin. Also if a patient has received heparin-ReoPro we will then almost always use Aprotinin. Aprotinin is a drug with several actions, one being to prevent platlet activation however it is also a very expensive drug, about $900 per patient. I think all of these disadvantages of ReoPro and advantages of Intergrillin are being recognized by the medical community; these are both patient safety factors and cost saving factors, two very powerful motivations in todays practice. Also if anyone noticed CORR beat 1st call estimates on the recently released earnings report. This is a good drug and IMHO CORR has a winner!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News